Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGMB-129 in Patients With Fibrostenotic Crohn's Disease
NCT05843578Phase 2Completed
- Sponsor
- Agomab Therapeutics
- Start
- Aug 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of ontunisertib in Crohn's disease, sponsored by Agomab Therapeutics. Started Aug 2023; status: completed.
02
Drugs
ontunisertib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05843578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843578.